ArcherDx
Jury Awards ArcherDx, MGH $4.7M in Qiagen Patent Infringement Lawsuit
A federal jury ruled that various Qiagen sample prep products infringe a pair of US patents underlying ArcherDx's anchored multiplex PCR technology.
Although the total number of deals went down in 2020, those deals were worth more compared to 2019 — four of the top five had billion-dollar price tags.
Invitae Q3 Revenues Increase 22 Percent
The firm generated $68.7 million in revenues compared to $56.5 million in Q3 2019 and exceeded the consensus Wall Street estimate.
Natera Sues Genosity for Patent Infringement Relating to ArcherDx Products
Natera claims that several Genosity products infringe its US Patent No. 10,732,220, titled "Methods for Simultaneous Amplification of Target Loci."
Federal Court Rejects ArcherDx Motion Against Natera in Patent Infringement Lawsuit
Last month, the court also ordered two separate patent lawsuits filed by Natera against ArcherDx this year to be consolidated into one.
Oct 5, 2020
Invitae Completes Acquisition of ArcherDx
Jun 7, 2020
ArcherDx Targeting $100M in IPO
Jan 10, 2020
ArcherDx, Illumina Agree to Comarket Future IVDs
Dec 17, 2019
ArcherDx Closes $55M Series C Financing
May 15, 2019